23 Result(s)
within
Marcello Moccia
Neurosciences
-
Article
Open AccessEffect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications
Circulating immune cells play a pathogenic role in multiple sclerosis (MS). However, the role of specific lymphocyte subpopulations is not unveiled yet, especially in progressive stages. We aimed to investigat...
-
Article
Open AccessChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis
ChatGPT is an open-source natural language processing software that replies to users’ queries. We conducted a cross-sectional study to assess people living with Multiple Sclerosis’ (PwMS) preferences, satisfac...
-
Article
Open AccessThe ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis
The wearing-off phenomenon is common in people with multiple sclerosis (MS) treated with ocrelizumab. We aim to evaluate the presence and severity of wearing-off to ocrelizumab in relation to demographic and M...
-
Article
Open AccessSARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose
COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential risks ass...
-
Article
Open AccessOcrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with p...
-
Article
Open AccessPersistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and r...
-
Article
Open AccessManagement of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
Patients with multiple sclerosis (MS) often receive disease-modifying therapies (DMTs) that can expose them to reactivation of potential occult hepatitis B virus (HBV) infection (pOBI). We aimed to evaluate th...
-
Article
Open AccessCorrection to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
-
Article
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study
Nabiximols is an effective treatment for spasticity in MS. However, treatment discontinuation over-time might occur and predictors of sustained treatment persistence over long-term follow-up in real-world sett...
-
Article
MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis
Different studies showed correlations between gadolinium-based contrast agent (GBCA) administrations and dentate nucleus (DN) T1-weighted hyperintensity. The clinical impact of gadolinium retention, however, i...
-
Article
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment
Both normal gray matter atrophy and brain tissue relaxation rates, in addition to total lesion volume, have shown significant correlations with cognitive test scores in multiple sclerosis (MS). Aim of the stud...
-
Article
Cardiovascular profile improvement during Natalizumab treatment
Cardiovascular comorbidities are associated with the risk of MS progression. Thus, we aim to measure variations of cardiovascular risk factors during Natalizumab treatment and their possible clinical associati...
-
Article
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study
In this independent, multicenter, retrospective study, we investigated the short-term persistence to treatment with first-line self-injectable or oral disease-modifying treatments (DMTs) in patients with relap...
-
Article
Lower serum uric acid is associated with mild cognitive impairment in early Parkinson’s disease: a 4-year follow-up study
Cognitive deficits are common in Parkinson’s disease (PD) and many patients eventually develop dementia; however, its occurrence is unpredictable. Serum uric acid (UA) has been proposed as a biomarker of PD, b...
-
Article
Serum uric acid is associated with apathy in early, drug-naïve Parkinson’s disease
Both low serum uric acid (UA) levels and apathy are considered biomarkers of cognitive decline and dementia in Parkinson’s disease (PD). There is an urgent need to combine different biomarkers to predict disea...
-
Article
Diagnostic challenges of Parkinsonism occurring in multiple sclerosis
-
Article
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study
Uric acid (UA) is reduced in multiple sclerosis (MS), and possibly relates to MS outcomes, with lower UA levels in subjects experiencing a relapse or presenting higher disability scores. The present retrospect...
-
Article
Erratum to: Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale
-
Article
Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale
Apathy is a behavioural disturbance occurring alone or in concomitance with depression in Parkinson’s disease (PD). Here we present a validation study for the self-report version of the Apathy Evaluation Scale...
-
Article
Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson’s disease
Tremor dominant (TD) and akinetic-rigid type (ART) are two motor subtypes of Parkinson’s disease associated with different disease progression and neurochemical/neuropathological features. The role of presynap...
